Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

Intratumor and Intertumor Heterogeneity in Melanoma. Transl Oncol (2017) 0.75

Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol (2011) 7.18

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol (2011) 2.53

Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One (2012) 2.40

Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays. Hum Pathol (2014) 2.10

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol (2013) 1.80

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer (2014) 1.79

Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn (2012) 1.66

The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med (2009) 1.56

Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS One (2013) 1.34

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget (2014) 1.33

Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice. Hum Pathol (2015) 1.13

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. Br J Cancer (2013) 1.08

The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br J Dermatol (2013) 1.07

Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma. Mod Pathol (2012) 1.02

Immunohistochemistry in the era of personalised medicine. J Clin Pathol (2012) 0.98

FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res (2014) 0.97

Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma. J Cutan Pathol (2014) 0.97

Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients. Tumour Biol (2014) 0.92

BRAF V600E mutation-specific antibody: A review. Semin Diagn Pathol (2015) 0.90

Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay. Sci Rep (2015) 0.87

NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas. Diagn Pathol (2015) 0.87

Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma. Hum Pathol (2014) 0.84

Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens. Tumour Biol (2014) 0.82

BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry. Am J Dermatopathol (2016) 0.81

Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France). J Eur Acad Dermatol Venereol (2015) 0.78

A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma? J Clin Pathol (2013) 0.77

Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer? Curr Drug Targets (2016) 0.77

Nuclear PARP1 expression and its prognostic significance in breast cancer patients. Tumour Biol (2015) 0.78